Journal Information
Vol. 101. Issue S1.
Experiencia clínica con etanercept. Nuevas perspectivas en la psoriasis y otras áreas de inflamación
Pages 18-25 (May 2010)
Vol. 101. Issue S1.
Experiencia clínica con etanercept. Nuevas perspectivas en la psoriasis y otras áreas de inflamación
Pages 18-25 (May 2010)
Full text access
Uso intermitente de etanercept en psoriasis
Intermittent use of etanercept in psoriasis
Visits
4613
E. Herrera
Corresponding author
eherrera@uma.es

Autor para correspondencia.
, A.J. Alcaide
Servicio de Dermatología. Hospital Universitario Virgen de la Victoria. Málaga. España
This item has received
Article information
Resumen

Para el tratamiento de la psoriasis en placas moderada-grave en España, hasta hace muy poco, únicamente estaba aprobado el uso de etanercept de forma intermitente o en ciclos de tratamiento no superiores a 24 semanas. A partir de septiembre de 2009 se aprobó su administración ininterrumpida para aquellos pacientes con psoriasis moderada-grave que, a criterio médico, así lo requieran. Esta decisión está avalada por los resultados de varios estudios que evaluaban la eficacia y seguridad de etanercept a corto y largo plazo, en terapia continua o intermitente. El estudio CRYSTEL evalúa la eficacia y seguridad de etanercept en tratamiento continuo o intermitente durante 54 semanas. Los resultados demostraron que tanto los pacientes que recibieron tratamiento continuo como los que recibieron tratamiento intermitente experimentaron mejorías significativas en su enfermedad y se mostraron muy satisfechos con el resultado, sin observarse hallazgos inesperados de seguridad en ambos grupos.

Palabras clave:
Etanercept
Terapia continua e intermitente
Eficacia y seguridad
Abstract

Systemic treatment for psoriasis has radically changed since the emergence of new biological therapies. One of these biological agents is etanercept. Until recently, the use of etanercept for treatment of moderate-to-severe psoriasis in Spain was only approved in an intermittent way or in cycles of treatment (not exceeding 24 weeks). However, from September 2009, its administration has been also approved in a continuous way for patients who require it. This decision is based on the results of several studies that evaluate the efficacy and safety of etanercept administrated in short and long term and in a continuous or intermittent therapy. One of these studies is Crystel study, what evaluates the efficacy and safety of continuous and paused etanercept regimens in psoriasis patients for 54-week-period. Crystel study results showed that both continuous and paused etanercept therapies improved PGA and PASI scores and patient satisfaction rates, no unexpected adverse effects were observed. Therefore, doctors may use one treatment or another according to patients needs.

Keywords:
Etanercept
Continuous or intermittent therapy
Efficacy and safety
Full text is only aviable in PDF
Bibliografía
[1.]
G. Specner-Green.
Etanercept (Enbrel): update on therapeutic use.
Ann Rheum Dis, 59 (2000), pp. 46-49
[2.]
C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, A. Wang, et al.
Etanercept as monotherapy in subjects with psoriasis.
N Engl J Med, 349 (2003), pp. 2014-2022
[3.]
K.B. Gordon, A.B. Gottlieb, C.L. Leonardi, B.E. Elewski, A. Wang, A. Jahreis, et al.
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.
J Dermatol Treat, 17 (2006), pp. 9-17
[4.]
W.H. Boehncke, R.A. Brasie, J. Barker, S. Chimenti, E. Dauden, M. de Rie, et al.
Recommendations for de use of etanercept in psoriasis: an european dermatology expert group consensus.
[5.]
K.A. Papp, S. Trying, M. Lahfa, J. Prinz, C.E. Griffiths, A.M. Nakanishi, et al.
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy and effect of dose reduction.
Br J Dermatol, 152 (2005), pp. 1304-1312
[6.]
A.B. Gottlieb, R.T. Matheson, N. Lowe, G.G. Krueger, S. Kang, B.S. Goffe, et al.
A randomized trial of etanercept as monotherapy for psoriasis.
Arch Dermatol, 139 (2003), pp. 1627-1632
[7.]
S. Tyring, K.B. Gordon, Y. Poulin, R.G. Langley, A.B. Gottlieb, M. Dunn, et al.
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Arch Dermatol, 143 (2007), pp. 719-726
[8.]
A. Moore, K.B. Gordon, S. Kang, A. Gottlieb, B. Freundlich, H.A. Xia, et al.
A randomized, open-label trial of continuous versus interrupted etanercetp therapy in the treatment of psoriasis.
J Am Acad Dermatol, 56 (2007), pp. 598-603
[9.]
J.P. Ortonne, C. Griffiths, E. Daudén, R. Strohal, D. Robertson, R. Pedersen, et al.
Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study.
Expert Rev Dermatol, 3 (2008), pp. 657-665
[10.]
Daudén E, Griffiths CEM, Ortonne JP, Kragballe K, Molta CT, Robertson D, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. JEADV. 2009 (en prensa).
[11.]
P. Van de Kerkhof, S. Segaert, M. Lahfa, T.A. Luger, Z. Karolyi, A. Kaszuba, et al.
Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis.
Br J Dermatol, 159 (2008), pp. 1177-1185
Copyright © 2010. Academia Española de Dermatología y Venereología
Download PDF
Idiomas
Actas Dermo-Sifiliográficas
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?